The performance of AlphaMissense to identify genes influencing disease.


Journal

HGG advances
ISSN: 2666-2477
Titre abrégé: HGG Adv
Pays: United States
ID NLM: 101772885

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 06 03 2024
revised: 18 08 2024
accepted: 19 08 2024
medline: 24 8 2024
pubmed: 24 8 2024
entrez: 24 8 2024
Statut: aheadofprint

Résumé

A novel algorithm, AlphaMissense, has been shown to have an improved ability to predict the pathogenicity of rare missense genetic variants. However, it is not known whether AlphaMissense improves the ability of gene-based testing to identify disease-influencing genes. Using whole-exome sequencing data from the UK Biobank, we compared gene-based association analysis strategies including sets of deleterious variants: predicted loss-of-function (pLoF) variants only, pLoF plus AlphaMissense pathogenic variants, pLoF with missense variants predicted to be deleterious by any of five commonly utilized annotation methods (Missense (1/5)) or only variants predicted to be deleterious by all five methods (Missense (5/5)). We measured performance to identify 519 previously identified positive control genes, which can lead to Mendelian diseases, or are the targets of successfully developed medicines. These strategies identified 850k pLoF variants and 5 million deleterious missense variants, including 22k likely pathogenic missense variants identified exclusively by AlphaMissense. The gene-based association tests found 608 significant gene associations (at P<1.25x10

Identifiants

pubmed: 39180217
pii: S2666-2477(24)00084-8
doi: 10.1016/j.xhgg.2024.100344
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100344

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Yiheng Chen (Y)

Department of Human Genetics, McGill University, Montréal, QC, Canada; Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada.

Guillaume Butler-Laporte (G)

Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada; Division of Infectious Diseases, Department of Medicine, McGill University.

Kevin Y H Liang (KYH)

Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada; Quantitative Life Sciences Program, McGill University, Montreal, Quebec, Canada.

Yann Ilboudo (Y)

Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada.

Summaira Yasmeen (S)

Computational Medicine, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.

Takayoshi Sasako (T)

Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada; Tanaka Diabetes Clinic Omiya, Saitama, Japan; Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Claudia Langenberg (C)

Precision Healthcare University Research Institute, Queen Mary University of London, London, UK; Computational Medicine, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.

Celia M T Greenwood (CMT)

Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.

J Brent Richards (JB)

Department of Human Genetics, McGill University, Montréal, QC, Canada; Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC, Canada; 5 Prime Sciences Inc, Montréal, Quebec, Canada; Department of Medicine, McGill University, Montréal, Quebec, Canada; Department of Twin Research, King's College London, London, UK. Electronic address: brent.richards@mcgill.ca.

Classifications MeSH